Before Valeant became a cautionary emblem, it was a Canadian company with a deeply modern idea: buy old drugs, cut research, raise prices, and let the balance sheet do the storytelling. The man who gave that idea its most formidable expression was Michael Pearson, a former McKinsey consultant and corporate strategist whose career had taught him to see industries as systems that could be simplified, sliced, and monetized. In the public record he was not accused of inventing a criminal enterprise in the way a counterfeit ring is invented. The more troubling truth, documented in securities filings, earnings calls, and later regulatory scrutiny, is that he built an operating philosophy that rewarded opacity, leverage, and speed over the slower disciplines of drug development.
Pearson took the helm of Valeant in 2008, after earlier leadership had already oriented the company toward acquisitive growth. But the period that mattered most began in the years after the financial crisis, when capital was cheap, investors were hungry for growth, and the pharmaceutical sector offered a particularly forgiving stage for complicated narratives. Specialty drug companies could point to patents, distribution channels, and reimbursement complexity as explanations for why their results could not be easily compared. That complexity was not a side effect. It was the environment. The system allowed a company to look like a scientific enterprise while behaving, in some respects, like a financial engineer.
The first important structural condition was debt. Valeant’s acquisition strategy depended on borrowed money and the confidence that future earnings would keep expanding enough to service it. That model required constant performance. Each new acquisition had to produce immediate accretion, each price increase had to be defended as rational, and each quarter had to look cleaner than the last. If organic growth was thin, it could be supplemented by accounting choices that emphasized adjusted earnings, non-GAAP metrics, and carefully managed revenue recognition. In the boardroom, these are not inherently fraudulent tools. But they create a temptation: if the market accepts your preferred measure of success, why not keep polishing it?
Another condition was the peculiar moral shelter of pharmaceuticals. A drug price increase can be defended as market-based if the underlying product remains legally available and clinically necessary. That makes outrage difficult to distinguish from business judgment. Valeant exploited that ambiguity, and investors initially rewarded it. The company’s market value rose on the promise of transformation, not discovery. It was an empire of bought assets, not laboratory breakthroughs. That distinction mattered because it meant the business had fewer natural brakes. There was no research pipeline to wait for, only transactions, integration, and the relentless need to justify the next acquisition.
The germ of the later scandal can be traced to one of the most consequential purchases in the pharmaceutical sector’s recent history: the 2013 acquisition of Bausch + Lomb, which deepened Valeant’s consumer and eye-care footprint. Such deals helped establish the pattern—buy, reprice, repackage, repeat. The company’s public face was disciplined and quantitative, but underneath that discipline was a structure that depended on constant momentum. It was a growth story with a narrow runway, and every quarter required a little more confidence, a little more financial choreography.
A second structural condition was the rise of specialty pharmacy distribution. In this world, drugs do not always move in straightforward channels. They can pass through intermediaries that manage dispensing, reimbursement, and patient coordination. That complexity can serve legitimate medical needs. It can also obscure who is buying what from whom, and at what price. Later scrutiny would focus on Philidor Rx Services, a specialty pharmacy that became central to allegations that Valeant was using a controlled distribution channel to book sales and accelerate revenue recognition. At the beginning, however, the arrangement looked like just another clever piece of commercial plumbing.
The founding lie was not a single false statement uttered at one desk on one day. It was subtler: the belief that a company could be judged mainly by the financial outcome of its maneuvering, while the means remained secondary so long as lawyers could defend them and accountants could footnote them. That belief traveled well among investors who liked execution stories and disliked uncertainty. It also proved hard to challenge because the underlying business was real. Valeant sold real drugs. Patients used them. Doctors prescribed them. The question was not whether the company existed. The question was whether its reported prosperity was being manufactured faster than the market could see.
By the time the structure was mature, the company’s own language had become a form of camouflage. Investors heard about synergy, discipline, and efficient capital allocation. Analysts heard about margin expansion and portfolio optimization. The same vocabulary that covered ordinary corporate ambition also covered something darker: a pressure system in which growth had to be kept visible at almost any cost. That is how many frauds begin—not with a forged check, but with a business model that quietly rewards concealment.
Inside that model, the first money began to flow in. The acquisitions closed, the debt funded them, and the reported numbers started to look like proof that the strategy worked. Yet the more the machine depended on speed and complexity, the more vulnerable it became to any interruption in confidence. The next step was not yet collapse. It was persuasion—convincing investors that the story on paper was the same as the company in the world, and that the price hikes and roll-ups were evidence of genius rather than warning signs. That pitch would soon become the whole enterprise.